← All indications
Tachycardia
Abnormally rapid heartbeat, usually with a HEART RATE above 100 beats per minute for adults. Tachycardia accompanied by disturbance in the cardiac depolarization (cardiac arrhythmia) is called tachyarrhythmia.
Subtype terms (4)
More specific conditions that are subtypes of Tachycardia in the MeSH hierarchy.
- Tachycardia, Paroxysmal
1 drug approved
- Tachycardia, Reciprocating
- Tachycardia, Supraventricular
8 drugs approved
- Tachycardia, Ventricular
39 drugs (35 approved, 4 experimental)
Drugs by status
Approved for this indication (2)
Phase 4 trials (14)
Phase 3 trials (8)
Phase 2 trials (20)
Phase 1 trials (3)
Organizations
Organization Involved with Phase 4 Indications (46)
- Bristol-Myers Squibb
- Amgen
- Gilead Sciences
- Pfizer
- Biosense Webster, Inc.
- St. Jude Medical
- Chong Kun Dang Pharmaceutical
- National Center for Research Resources (NCRR)
- Connolly, Stuart, M.D.
- Nova Scotia Health Authority
- University of Pennsylvania
- Cardiovascular Consultants of Nevada
- Centre Hospitalier Universitaire de Nīmes
- Harvard University
- Hospital General Universitario Gregorio Marañon
- Loyola University
- McMaster University
- Seoul National University
- Shengjing Hospital
- Universidad Autonoma de Madrid
- Universidad Complutense de Madrid
- Universidade Ibirapuera
- University of Kansas
- University of Milan
- University of Ottawa
- University of Pavia
- University of Toronto
- University of British Columbia
- Vanderbilt University
- Icahn School of Medicine at Mount Sinai
- +16 more
Organization Involved with Phase 3 Indications (24)
- Baxalta
- Hamilton Health Sciences Corporation
- Milestone Pharmaceuticals Inc.
- Newmarket Electrophysiology Research Group Inc
- National Institutes of Health (NIH)
- National Heart, Lung, and Blood Institute (NHLBI)
- United States Army
- The Hospital for Sick Children
- American Heart Association
- University of London
- Cornell University
- Duke University
- University of Washington
- Johns Hopkins University
- University of Pretoria
- University of Alberta
- University of California, San Diego
- University of Utah
- Medpace, Inc.
- Policlinico Casilino
- Methodist Cancer Center, Houston, Texas
- Defence Research and Development Canada
- Ono Pharmaceuticals
- IQVIA
Organization Involved with Phase 2 Indications (18)
- Grifols
- Sanofi
- Wyeth
- Aarhus University
- Gottfried Wilhelm Leibniz Universität Hannover
- New York Medical College
- Mayo Clinic
- Aalborg University
- Tel Aviv University
- University of Calgary
- Moscow State University
- Chiangmai University
- Humboldt University
- Medtronic
- Lundbeck
- University of Picardie Jules Verne
- The University of Texas, Dallas
- Dysautonomia International
Organization Involved with Phase 1 Indications (4)
Organization Involved with Other Experimental Indications (19)
- Fundação de Amparo à Pesquisa do Estado de São Paulo
- University of Pittsburgh
- Ain Shams University
- Georgetown University
- Mercy Research
- New York University
- Northwell Health
- University of Iowa
- University of Maryland
- University of Oklahoma
- Mercy Health Research
- State University of New York, Brooklyn
- Care Hospital, Hyderabad
- Washington University in St. Louis
- Bengbu Medical College
- General Electric
- Government of Brazil
- University of Bridgeport
- Jiangsu University